Genocea Biosciences, Inc.
10
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Role: lead
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Role: lead
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
Role: lead
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
Role: lead
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
Role: lead
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
Role: lead
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
Role: lead
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
Role: lead
Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study
Role: lead
Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine
Role: lead
All 10 trials loaded